<DOC>
	<DOC>NCT00051142</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Adult patients of any race and either sex with openangle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>